Tempus presents real-world study linking KMT2C mutation to platinum therapy survival gain
PUBT · 10h ago
Share
Listen to the news
- Tempus disclosed new real-world evidence research that links KMT2C mutations to better outcomes on platinum-based chemotherapy in solid tumors.
- Findings were already validated in an external cancer dataset, with an oral presentation scheduled for AACR Annual Meeting 2026 on April 20 in San Diego.
- Colorectal cancer showed strongest signal, positioning KMT2C as potential biomarker to guide chemotherapy selection in GI cancers.
- Tempus indicated follow-on laboratory work is underway to clarify biological drivers, supporting potential clinical adoption and partner interest in biomarker-led treatment strategies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260414517979) on April 14, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved